A non-arthropathic dose and its disposition following repeated oral administration of ofloxacin, a new quinolone antimicrobial agent, to juvenile dogs

A non-arthropathic dose and disposition of ofloxacin, a potent new quinolone antimicrobial agent, were assessed in male juvenile (3-month-oid) dogs, when administered orally at 5, 10 and 20 mg/kg/day once daily for 8 consecutive days. Ofloxacin concentrations in sera and articular cartilages were an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Veterinary Medical Science 2001, Vol.63(8), pp.867-872
Hauptverfasser: Yabe, K. (Daiichi Pharmaceutical Co. Ltd., Tokyo (Japan)), Murakami, Y, Nishida, S, Sekiguchi, M, Furuhama, K, Goryo, M, Okada, K
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 872
container_issue 8
container_start_page 867
container_title Journal of Veterinary Medical Science
container_volume 63
creator Yabe, K. (Daiichi Pharmaceutical Co. Ltd., Tokyo (Japan))
Murakami, Y
Nishida, S
Sekiguchi, M
Furuhama, K
Goryo, M
Okada, K
description A non-arthropathic dose and disposition of ofloxacin, a potent new quinolone antimicrobial agent, were assessed in male juvenile (3-month-oid) dogs, when administered orally at 5, 10 and 20 mg/kg/day once daily for 8 consecutive days. Ofloxacin concentrations in sera and articular cartilages were analyzed by high-performance liquid chromatography (HPLC). Macroscopically, arthropathy characterized by fluid-filled vesicles in articular surface of the humerus and femur was observed in animals receiving 10 and 20 mg/kg/day of ofloxacin, but not in those given 5 mg/kg/day. At 20 mg/kg/day, arthropathy of comparable severity also occurred on day 2. Microscopically, the cavity formation in the middle zone of the articular cartilage was first identified and then necrotic chondrocytes were found numerous around the cavity, followed by appearance of chondrocyte clusters. In pharmacokinetics, peak serum concentration (C sub(max)) and area under the concentrations (AUC sub(0 - 24)) were increased in a dose-dependent manner. However, no remarkable differences in these two parameters were noted between a single and repeated treatments, suggesting no accumulation of the drug. The articular ofloxacin concentration 2 hr after treatment was approximately 1.8 (day 2) to 2.0 times (day 8) higher than the serum concentration. Based on these results, a non-arthropathic dose of ofloxacin in male juvenile dogs following an 8-day treatment is considered to be 5 mg/kg/day, and its C sub(max) , AUC sub(0 - 24) and articular cartilage concentrations 2 hr after treatment were 3.4 micro g /ml, 35.1 micro g /hr/ml and 7.0 micro g /g, respectively, under these experimental conditions. Thus, arthropathy due to ofloxacin may be predicted by monitoring serum drug concentration.
doi_str_mv 10.1292/jvms.63.867
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19680377</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3158532321</sourcerecordid><originalsourceid>FETCH-LOGICAL-c676t-b3f20a5c6ee206a736c902f6e446790b4bdc2c161f54d08f472dde14e0cffbd93</originalsourceid><addsrcrecordid>eNpdkl9v1SAYhxujccfpldcaEhNvXI9AW9rebVk2_2SJXug1ofByDg2FM6CbfhE_r9SebIkJgQseHnjfH0XxmuAtoT39ON5NccuqbcfaJ8WGVHVbtnXVPy02uCesbGmDT4oXMY4YU1Kz_nlxQkjTdE1NNsWfC-S8K0VI--APIu2NRMpHQMIpZFJEysSDjyYZ75D21vp743YowAFEAoV8EBYJNRlnYgriH-Z1Htb_EtK4MySQg3t0OxvnrXeLOJnJyOAHsxzdgUtnKHk0znfgjIV8_S6-LJ5pYSO8Oq6nxc_rqx-Xn8ubb5--XF7clJK1LJVDpSkWjWQAFDPRVkz2mGoGdc3aHg_1oCSVhBHd1Ap3um6pUkBqwFLrQfXVafF-9R6Cv50hJj6ZKMFa4cDPkZOedbhq2wy--w8c_RxcfhvPPe1YV3XdovuwUrm8GANofghmEuE3J5gvYfElLM4qnsPK9Nujcx4mUI_sMZ0MnK_AGFNu1AOQ0zLSwqNsnbLzYUvuReDgsuLNqtDCc7ELJvKv32n-CRiTXFz1F70vs_8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1468683889</pqid></control><display><type>article</type><title>A non-arthropathic dose and its disposition following repeated oral administration of ofloxacin, a new quinolone antimicrobial agent, to juvenile dogs</title><source>J-STAGE Free</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Yabe, K. (Daiichi Pharmaceutical Co. Ltd., Tokyo (Japan)) ; Murakami, Y ; Nishida, S ; Sekiguchi, M ; Furuhama, K ; Goryo, M ; Okada, K</creator><creatorcontrib>Yabe, K. (Daiichi Pharmaceutical Co. Ltd., Tokyo (Japan)) ; Murakami, Y ; Nishida, S ; Sekiguchi, M ; Furuhama, K ; Goryo, M ; Okada, K</creatorcontrib><description>A non-arthropathic dose and disposition of ofloxacin, a potent new quinolone antimicrobial agent, were assessed in male juvenile (3-month-oid) dogs, when administered orally at 5, 10 and 20 mg/kg/day once daily for 8 consecutive days. Ofloxacin concentrations in sera and articular cartilages were analyzed by high-performance liquid chromatography (HPLC). Macroscopically, arthropathy characterized by fluid-filled vesicles in articular surface of the humerus and femur was observed in animals receiving 10 and 20 mg/kg/day of ofloxacin, but not in those given 5 mg/kg/day. At 20 mg/kg/day, arthropathy of comparable severity also occurred on day 2. Microscopically, the cavity formation in the middle zone of the articular cartilage was first identified and then necrotic chondrocytes were found numerous around the cavity, followed by appearance of chondrocyte clusters. In pharmacokinetics, peak serum concentration (C sub(max)) and area under the concentrations (AUC sub(0 - 24)) were increased in a dose-dependent manner. However, no remarkable differences in these two parameters were noted between a single and repeated treatments, suggesting no accumulation of the drug. The articular ofloxacin concentration 2 hr after treatment was approximately 1.8 (day 2) to 2.0 times (day 8) higher than the serum concentration. Based on these results, a non-arthropathic dose of ofloxacin in male juvenile dogs following an 8-day treatment is considered to be 5 mg/kg/day, and its C sub(max) , AUC sub(0 - 24) and articular cartilage concentrations 2 hr after treatment were 3.4 micro g /ml, 35.1 micro g /hr/ml and 7.0 micro g /g, respectively, under these experimental conditions. Thus, arthropathy due to ofloxacin may be predicted by monitoring serum drug concentration.</description><identifier>ISSN: 0916-7250</identifier><identifier>EISSN: 1347-7439</identifier><identifier>DOI: 10.1292/jvms.63.867</identifier><identifier>PMID: 11558541</identifier><language>eng</language><publisher>Japan: JAPANESE SOCIETY OF VETERINARY SCIENCE</publisher><subject>Administration, Oral ; Animals ; Anti-Infective Agents - administration &amp; dosage ; Anti-Infective Agents - adverse effects ; Anti-Infective Agents - pharmacokinetics ; ANTIMICROBIALS ; Area Under Curve ; arthropathy ; Cartilage, Articular - drug effects ; Cartilage, Articular - pathology ; Chromatography, High Pressure Liquid - veterinary ; DOGS ; Dogs - metabolism ; Dose-Response Relationship, Drug ; Femur - drug effects ; Femur - pathology ; Humerus - drug effects ; Humerus - pathology ; JOINT DISEASES ; juvenile dog ; Male ; MEDICINAL PROPERTIES ; non-arthropathic dose ; ofloxacin ; Ofloxacin - administration &amp; dosage ; Ofloxacin - adverse effects ; Ofloxacin - pharmacokinetics ; ORAL ADMINISTRATION ; pharmacokinetics ; QUINOLINES ; YOUNG ANIMALS</subject><ispartof>Journal of Veterinary Medical Science, 2001, Vol.63(8), pp.867-872</ispartof><rights>2001 by the Japanese Society of Veterinary Science</rights><rights>Copyright Japan Science and Technology Agency 2001</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c676t-b3f20a5c6ee206a736c902f6e446790b4bdc2c161f54d08f472dde14e0cffbd93</citedby><cites>FETCH-LOGICAL-c676t-b3f20a5c6ee206a736c902f6e446790b4bdc2c161f54d08f472dde14e0cffbd93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1876,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11558541$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yabe, K. (Daiichi Pharmaceutical Co. Ltd., Tokyo (Japan))</creatorcontrib><creatorcontrib>Murakami, Y</creatorcontrib><creatorcontrib>Nishida, S</creatorcontrib><creatorcontrib>Sekiguchi, M</creatorcontrib><creatorcontrib>Furuhama, K</creatorcontrib><creatorcontrib>Goryo, M</creatorcontrib><creatorcontrib>Okada, K</creatorcontrib><title>A non-arthropathic dose and its disposition following repeated oral administration of ofloxacin, a new quinolone antimicrobial agent, to juvenile dogs</title><title>Journal of Veterinary Medical Science</title><addtitle>J. Vet. Med. Sci.</addtitle><description>A non-arthropathic dose and disposition of ofloxacin, a potent new quinolone antimicrobial agent, were assessed in male juvenile (3-month-oid) dogs, when administered orally at 5, 10 and 20 mg/kg/day once daily for 8 consecutive days. Ofloxacin concentrations in sera and articular cartilages were analyzed by high-performance liquid chromatography (HPLC). Macroscopically, arthropathy characterized by fluid-filled vesicles in articular surface of the humerus and femur was observed in animals receiving 10 and 20 mg/kg/day of ofloxacin, but not in those given 5 mg/kg/day. At 20 mg/kg/day, arthropathy of comparable severity also occurred on day 2. Microscopically, the cavity formation in the middle zone of the articular cartilage was first identified and then necrotic chondrocytes were found numerous around the cavity, followed by appearance of chondrocyte clusters. In pharmacokinetics, peak serum concentration (C sub(max)) and area under the concentrations (AUC sub(0 - 24)) were increased in a dose-dependent manner. However, no remarkable differences in these two parameters were noted between a single and repeated treatments, suggesting no accumulation of the drug. The articular ofloxacin concentration 2 hr after treatment was approximately 1.8 (day 2) to 2.0 times (day 8) higher than the serum concentration. Based on these results, a non-arthropathic dose of ofloxacin in male juvenile dogs following an 8-day treatment is considered to be 5 mg/kg/day, and its C sub(max) , AUC sub(0 - 24) and articular cartilage concentrations 2 hr after treatment were 3.4 micro g /ml, 35.1 micro g /hr/ml and 7.0 micro g /g, respectively, under these experimental conditions. Thus, arthropathy due to ofloxacin may be predicted by monitoring serum drug concentration.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Anti-Infective Agents - administration &amp; dosage</subject><subject>Anti-Infective Agents - adverse effects</subject><subject>Anti-Infective Agents - pharmacokinetics</subject><subject>ANTIMICROBIALS</subject><subject>Area Under Curve</subject><subject>arthropathy</subject><subject>Cartilage, Articular - drug effects</subject><subject>Cartilage, Articular - pathology</subject><subject>Chromatography, High Pressure Liquid - veterinary</subject><subject>DOGS</subject><subject>Dogs - metabolism</subject><subject>Dose-Response Relationship, Drug</subject><subject>Femur - drug effects</subject><subject>Femur - pathology</subject><subject>Humerus - drug effects</subject><subject>Humerus - pathology</subject><subject>JOINT DISEASES</subject><subject>juvenile dog</subject><subject>Male</subject><subject>MEDICINAL PROPERTIES</subject><subject>non-arthropathic dose</subject><subject>ofloxacin</subject><subject>Ofloxacin - administration &amp; dosage</subject><subject>Ofloxacin - adverse effects</subject><subject>Ofloxacin - pharmacokinetics</subject><subject>ORAL ADMINISTRATION</subject><subject>pharmacokinetics</subject><subject>QUINOLINES</subject><subject>YOUNG ANIMALS</subject><issn>0916-7250</issn><issn>1347-7439</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkl9v1SAYhxujccfpldcaEhNvXI9AW9rebVk2_2SJXug1ofByDg2FM6CbfhE_r9SebIkJgQseHnjfH0XxmuAtoT39ON5NccuqbcfaJ8WGVHVbtnXVPy02uCesbGmDT4oXMY4YU1Kz_nlxQkjTdE1NNsWfC-S8K0VI--APIu2NRMpHQMIpZFJEysSDjyYZ75D21vp743YowAFEAoV8EBYJNRlnYgriH-Z1Htb_EtK4MySQg3t0OxvnrXeLOJnJyOAHsxzdgUtnKHk0znfgjIV8_S6-LJ5pYSO8Oq6nxc_rqx-Xn8ubb5--XF7clJK1LJVDpSkWjWQAFDPRVkz2mGoGdc3aHg_1oCSVhBHd1Ap3um6pUkBqwFLrQfXVafF-9R6Cv50hJj6ZKMFa4cDPkZOedbhq2wy--w8c_RxcfhvPPe1YV3XdovuwUrm8GANofghmEuE3J5gvYfElLM4qnsPK9Nujcx4mUI_sMZ0MnK_AGFNu1AOQ0zLSwqNsnbLzYUvuReDgsuLNqtDCc7ELJvKv32n-CRiTXFz1F70vs_8</recordid><startdate>20010801</startdate><enddate>20010801</enddate><creator>Yabe, K. (Daiichi Pharmaceutical Co. Ltd., Tokyo (Japan))</creator><creator>Murakami, Y</creator><creator>Nishida, S</creator><creator>Sekiguchi, M</creator><creator>Furuhama, K</creator><creator>Goryo, M</creator><creator>Okada, K</creator><general>JAPANESE SOCIETY OF VETERINARY SCIENCE</general><general>Japan Science and Technology Agency</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QR</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7QO</scope><scope>7T7</scope><scope>C1K</scope></search><sort><creationdate>20010801</creationdate><title>A non-arthropathic dose and its disposition following repeated oral administration of ofloxacin, a new quinolone antimicrobial agent, to juvenile dogs</title><author>Yabe, K. (Daiichi Pharmaceutical Co. Ltd., Tokyo (Japan)) ; Murakami, Y ; Nishida, S ; Sekiguchi, M ; Furuhama, K ; Goryo, M ; Okada, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c676t-b3f20a5c6ee206a736c902f6e446790b4bdc2c161f54d08f472dde14e0cffbd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Anti-Infective Agents - administration &amp; dosage</topic><topic>Anti-Infective Agents - adverse effects</topic><topic>Anti-Infective Agents - pharmacokinetics</topic><topic>ANTIMICROBIALS</topic><topic>Area Under Curve</topic><topic>arthropathy</topic><topic>Cartilage, Articular - drug effects</topic><topic>Cartilage, Articular - pathology</topic><topic>Chromatography, High Pressure Liquid - veterinary</topic><topic>DOGS</topic><topic>Dogs - metabolism</topic><topic>Dose-Response Relationship, Drug</topic><topic>Femur - drug effects</topic><topic>Femur - pathology</topic><topic>Humerus - drug effects</topic><topic>Humerus - pathology</topic><topic>JOINT DISEASES</topic><topic>juvenile dog</topic><topic>Male</topic><topic>MEDICINAL PROPERTIES</topic><topic>non-arthropathic dose</topic><topic>ofloxacin</topic><topic>Ofloxacin - administration &amp; dosage</topic><topic>Ofloxacin - adverse effects</topic><topic>Ofloxacin - pharmacokinetics</topic><topic>ORAL ADMINISTRATION</topic><topic>pharmacokinetics</topic><topic>QUINOLINES</topic><topic>YOUNG ANIMALS</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yabe, K. (Daiichi Pharmaceutical Co. Ltd., Tokyo (Japan))</creatorcontrib><creatorcontrib>Murakami, Y</creatorcontrib><creatorcontrib>Nishida, S</creatorcontrib><creatorcontrib>Sekiguchi, M</creatorcontrib><creatorcontrib>Furuhama, K</creatorcontrib><creatorcontrib>Goryo, M</creatorcontrib><creatorcontrib>Okada, K</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Chemoreception Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Journal of Veterinary Medical Science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yabe, K. (Daiichi Pharmaceutical Co. Ltd., Tokyo (Japan))</au><au>Murakami, Y</au><au>Nishida, S</au><au>Sekiguchi, M</au><au>Furuhama, K</au><au>Goryo, M</au><au>Okada, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A non-arthropathic dose and its disposition following repeated oral administration of ofloxacin, a new quinolone antimicrobial agent, to juvenile dogs</atitle><jtitle>Journal of Veterinary Medical Science</jtitle><addtitle>J. Vet. Med. Sci.</addtitle><date>2001-08-01</date><risdate>2001</risdate><volume>63</volume><issue>8</issue><spage>867</spage><epage>872</epage><pages>867-872</pages><issn>0916-7250</issn><eissn>1347-7439</eissn><abstract>A non-arthropathic dose and disposition of ofloxacin, a potent new quinolone antimicrobial agent, were assessed in male juvenile (3-month-oid) dogs, when administered orally at 5, 10 and 20 mg/kg/day once daily for 8 consecutive days. Ofloxacin concentrations in sera and articular cartilages were analyzed by high-performance liquid chromatography (HPLC). Macroscopically, arthropathy characterized by fluid-filled vesicles in articular surface of the humerus and femur was observed in animals receiving 10 and 20 mg/kg/day of ofloxacin, but not in those given 5 mg/kg/day. At 20 mg/kg/day, arthropathy of comparable severity also occurred on day 2. Microscopically, the cavity formation in the middle zone of the articular cartilage was first identified and then necrotic chondrocytes were found numerous around the cavity, followed by appearance of chondrocyte clusters. In pharmacokinetics, peak serum concentration (C sub(max)) and area under the concentrations (AUC sub(0 - 24)) were increased in a dose-dependent manner. However, no remarkable differences in these two parameters were noted between a single and repeated treatments, suggesting no accumulation of the drug. The articular ofloxacin concentration 2 hr after treatment was approximately 1.8 (day 2) to 2.0 times (day 8) higher than the serum concentration. Based on these results, a non-arthropathic dose of ofloxacin in male juvenile dogs following an 8-day treatment is considered to be 5 mg/kg/day, and its C sub(max) , AUC sub(0 - 24) and articular cartilage concentrations 2 hr after treatment were 3.4 micro g /ml, 35.1 micro g /hr/ml and 7.0 micro g /g, respectively, under these experimental conditions. Thus, arthropathy due to ofloxacin may be predicted by monitoring serum drug concentration.</abstract><cop>Japan</cop><pub>JAPANESE SOCIETY OF VETERINARY SCIENCE</pub><pmid>11558541</pmid><doi>10.1292/jvms.63.867</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0916-7250
ispartof Journal of Veterinary Medical Science, 2001, Vol.63(8), pp.867-872
issn 0916-7250
1347-7439
language eng
recordid cdi_proquest_miscellaneous_19680377
source J-STAGE Free; MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Administration, Oral
Animals
Anti-Infective Agents - administration & dosage
Anti-Infective Agents - adverse effects
Anti-Infective Agents - pharmacokinetics
ANTIMICROBIALS
Area Under Curve
arthropathy
Cartilage, Articular - drug effects
Cartilage, Articular - pathology
Chromatography, High Pressure Liquid - veterinary
DOGS
Dogs - metabolism
Dose-Response Relationship, Drug
Femur - drug effects
Femur - pathology
Humerus - drug effects
Humerus - pathology
JOINT DISEASES
juvenile dog
Male
MEDICINAL PROPERTIES
non-arthropathic dose
ofloxacin
Ofloxacin - administration & dosage
Ofloxacin - adverse effects
Ofloxacin - pharmacokinetics
ORAL ADMINISTRATION
pharmacokinetics
QUINOLINES
YOUNG ANIMALS
title A non-arthropathic dose and its disposition following repeated oral administration of ofloxacin, a new quinolone antimicrobial agent, to juvenile dogs
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T10%3A25%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20non-arthropathic%20dose%20and%20its%20disposition%20following%20repeated%20oral%20administration%20of%20ofloxacin,%20a%20new%20quinolone%20antimicrobial%20agent,%20to%20juvenile%20dogs&rft.jtitle=Journal%20of%20Veterinary%20Medical%20Science&rft.au=Yabe,%20K.%20(Daiichi%20Pharmaceutical%20Co.%20Ltd.,%20Tokyo%20(Japan))&rft.date=2001-08-01&rft.volume=63&rft.issue=8&rft.spage=867&rft.epage=872&rft.pages=867-872&rft.issn=0916-7250&rft.eissn=1347-7439&rft_id=info:doi/10.1292/jvms.63.867&rft_dat=%3Cproquest_cross%3E3158532321%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1468683889&rft_id=info:pmid/11558541&rfr_iscdi=true